Neurodevelopmental effects of prenatal exposure to psychotropic medications

Depression and Anxiety

Volumn 27, Issue 7, 2010, Pages 675-686

  Gentile, Salvatore ^a  

^a ASL Salerno   (Italy)

Author keywords

Developmental outcome; Pregnancy; Psychotropic drugs

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CITALOPRAM; CLONAZEPAM; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; LAMOTRIGINE; LITHIUM; MEPROBAMATE; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; PHENOTHIAZINE; PROMETHAZINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ARTICLE; BRAIN DEVELOPMENT; CHILD BEHAVIOR; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG SAFETY; HUMAN; INTELLIGENCE QUOTIENT; MATERNAL STRESS; MENTAL DEVELOPMENT; MOOD CHANGE; MOTOR DEVELOPMENT; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE; PRIORITY JOURNAL; TEMPERAMENT; TERATOGENESIS; BRAIN; CHILD; CHILD DEVELOPMENT; COGNITION; DRUG EFFECTS; FEMALE; GROWTH, DEVELOPMENT AND AGING; INFANT; MENTAL DISORDERS; PREGNANCY COMPLICATIONS; PRESCHOOL CHILD; PSYCHOLOGY;

BRAIN; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COGNITION; FEMALE; HUMANS; INFANT; MENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOTROPIC DRUGS;

EID: 77956823529     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20706     Document Type: Article

References (101)

1. Gentile S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: Focus on emerging mood stabilizers. Bipolar Disord 2006;8:207-220.
2. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord 2004;6:2-13.
3. Yonkers KA,Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and postpartum period. Am J Psychiatry 2005;161:608-620.
4. Kumar R, Robson MK. A prospective study of emotional disorders in childbearing women. Br J Psychiatry 1984;144: 35-47.
5. Sundstrom IM, Bixio M, Bjorn I, et al. Prevalence of psychiatric disorders in gynaecologic outpatients. Am J Obstet Gynecol 2001;184:8-13.
6. Nerizoglu FN, Anemone MA, Yaryura-Tobias JA. Onset of obsessive-compulsive disorder in pregnancy. Am J Psychiatry 1992;149:947-950.
7. Williams KE, Koran L. Onset of obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstrum. J Clin Psychiatry 1997;58:330-334.
8. Vythilingum B. Anxiety disorders in pregnancy. Curr Psychiatr Rep 2008;10:331-335.
9. Guler O, Sahin FK, Emul HM, et al. The prevalence of panic disorder in pregnant women during the third trimester of pregnancy. Compr Psychiatry 2008;49:154-158.
10. Hertzberg T, Wahlbeck K. The impact of pregnancy and puerperium on panic disorder: A review. J Psychosom Obstet Gynaecol 1999;20:59-64.
11. Zoler ML. Bipolar boosts depression risk during pregnancy: Findings suggest "urgent need" for better screening and detection of bipolar-spectrum disorders. Health Care Industry Buzz. bBNET. Available from: Http://findarticles.com/p/ articles/mi-hb4345/is-8-33/ai-n29203131/ Accessed September 23, 2009.
12. Freeman MP, Smith KW, freeman SA, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry 2002;63:284-287.
13. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2008 Sep 11. [Epub ahead of print].
14. Wartkins ME, Newport J. Psychosis in pregnancy. Obstet Gynecol 2009;116:1349-1350.
15. McNeil TF, Kaij L, Malmquiat-Larsson A. Women with nonorganic psychosis: Pregnancy's effect on mental health during pregnancy. Obstetric complications in schizophrenic patients. Acta Psychiatr Scand 1984;70:140-148.
16. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Epidemiol Rev 1995;15:165-171.
17. Stott DH. Follow-up study from birth of the effects of prenatal stresses. Dev Med Child Neurol 1973;15:770-787.
18. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and anxiety in early pregnancy and risk of preeclampsia. Obstet Ginecol 2000;95:487-490.
19. Gentile S. The clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother 2004;38: 1265-1271.
20. Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellanich LA. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005;162:79-91.
21. Vorhees C, Brunner R, Butcher R. Psychotropic drugs as behavioral teratogens. Science 1979;205:1220-1225.
22. Vernadakis A, Parker KK. Drugs and the developing central nervous system. Pharmacol Ther 1980;11:593-647.
23. Vartazarmian R, Malik S, Baker GB, Boksa P. Long-term effects of fluoxetine or vehicle administration during pregnancy on behavioral outcomes in guinea pig offsprings. Psychopharmacol 2005;178:328-338.
24. Morrison JL, Riggs KW, Chien C, Gruber N, Mc Millen IC, Rurak DW. Chronic maternal fluoxetine infusion in pregnant sheep: Effects on the maternal and fetal hypothalamic-pituitaryadrenal axes. Pediatr Res 2004;56:40-46.
25. Xu Y, Sari Y, Zhou FC. Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development. Brain Res Dev Brain Res 2004;150: 151-161.
26. Cohen L, Rosembaum J. Psychotropic drugs use during pregnancy: Weighing the risk. J Clin Psychiatry 1998;59:18-28.
27. Koren G, Pastuszak A. Drugs in pregnancy. N Engl J Med 1998;338:1128-1137.
28. Nulman I, Koren G. The safety of fluoxetine during pregnancy. Teratology 1996;53:304-308.
29. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drug. New Engl J Med 1997;336:258-262.
30. Reebye PR, Morison SJ, Pannikar H, Misri S, Grunau RE. Affect expression in prenatally psychotropic exposed and nonexposed mother-infant dyad. Inf Ment Health J 2002;23: 403-416.
31. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: A prospective, controlled study. Am J Psychiatry 2002;159:1889-1895.
32. Morison SJ, Grunau RE, Oberlander TF, Misri S, Pannikar H, Reebye P. Infant social behavior and development in the first year of life following prolonged prenatal psychotropic medication exposure [Abstract]. Pediatr Res 2001;49:28A.
33. Mattson S, Eastvold A, Jones K, Harris J, Chambers C. Neurobehavioral follow-up of children prenatally exposed to fluoxetine [Abstract]. Teratology 1999;59:376.
34. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004;65:230-237.
35. Misri S, Reebye P, Kendrick K, Carter D, Grunau RE, Oberlander TF. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 2006;163:1026-1032.
36. Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007;161:22-29.
37. Hekkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002;72: 184-191.
38. Casper RC, Fleisher BE, Julie Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003;4: 402-408.
39. Mortensen JT, Olsen J, Larsen H, Bendsen J, Obel C, Sørensen HAT. Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur J Epidemiol 2003;18:769-771.
40. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010;125:e600-e608.
41. Štika L, Elisova K, Honzáková H, et al. Effects of drug administration in pregnancy on children's school behaviour. Pharm Weekbl [Sci] 1990;12:252-255.
42. Czeizel AE, Szegal BA, Joffe JM, Racz J. The effect of diazepam and promethazine treatment during pregnancy on the somatic development of human offspring. Neurotoxicol Teratol 1999;21:157-167.
43. Hartz SC, Heinonen OP, Shapiro S, Siskind V, Slone D. Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. New Engl J Med 1975;292:726-728.
44. Viggedal G, Hagberg BS, Laegreid L, Aronsson M. Mental development in late infancy after prenatal exposure to benzodiazepines-a prospective study. J Child Psychol Psychiatry 1993;3:295-305.
45. Gidai J, Acs N, Bánhidy F, Czeizel AE. An evaluation of data for 10 children born to mothers who attempred suicide by taking large dose of alprazolam during pregnancy. Toxicol Industr Health 2008;34:53-60.
46. Jacobson SJ, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992;339:530-533.
47. Shou M. What happened later to the lithium babies? A followup study of children born without malformations. Acta Psychiatr Scand 1976;54:193-197.
48. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994;271:767-770.
49. Gladstone DJ, Bologa M, Maguire C, Pastuszak A, Koren G. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: A prospective study. Repr Toxicol 1992;6:257-261.
50. Meador KJ, Baker GA, Browning N, et al. Cognitive functions at 3 years after fetal exposure to antiepileptic drugs. New Engl J Med 2009;360:1597-1605.
51. van der Pol MC, Hadders-Algra M, Huisjes H, Touwen BCL. Antiepileptic medications in pregnancy: Late effects on the children's central nervous system development. Am J Obstet Gynecol 1991;161:121-128.
52. Titze K, Koch S, Helge H, Lehmkuhl U, Rauh H, Steinhausen HC. Prenatal and family risk of children born to mothers with epilepsy: Effects on cognitive development. Dev Med Child Neurol 2008;50:117-122.
53. Eriksson K, Viinikainen V, Mönkkönen A, et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epil Res 2005;65:189-200.
54. Wide K, Winbladh B, Tomson T, Sars-Zimmer K, Berggren E. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: A prospective population- based study. Dev Med Child Neurol 2000;42:87-92.
55. Katz JM, Pacia SV, Devinsky O. Current management of epilepsy and pregnancy: Fetal outcome, congenital malformations, and developmental delay. Epil Behav 2001;2:119-123.
56. Arulmozhi T, Dhanaraj M, Rangaraj R, Vengatesan A. Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurol India 2006;54:42-47.
57. Thomas SV, Sukumaran S, Lukose N, George A, Sarma PS. Intellectual and language functions in children of mothers with epilepsy. Epilepsia 2007;48:2234-2240.
58. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004;62:28-32.
59. Adab N, Kini U, Ayres J, et al. The longer outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-1583.
60. Vinten JV, Adab N, Kini U, Gorry J, Gregg J, Baker GA, for the Liverpool and Manchester Neurodevelopmental Study Group. Neuropsychological effects of exposure to anticonvulsant medications in utero. Neurology 2005;64:949-954.
61. Dean JCS, Hailey H, Moore SJ, Turpenny PD, Little J. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Gen 2002;39: 251-259.
62. Otsuka Y, Silver K, Lopes-Cendes I, Anderman E, Tsuda T. Effects of antiepileptic drugs on psychomotor development in offspring of epileptic mothers [Abstract]. Epilepsia 1999;40: 296.
63. McVearry K, Gaillard W, VanMeter J, Meador KJ. Prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epil Behav 2009;16:609-616.
64. Viinikainen K, Eriksson K, Mönkkönen A, et al. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epil Behav 2006;9:636-640.
65. Koch S, Jäger-Roman E, Lösche G, Rating D, Helge H. Antiepileptic drug treatment during pregnancy: Drug side effects in the neonate and neurological outcome. Acta Paediatr 1996;84:739-746.
66. Thomas SV, Ajaykumar B, Sindhu K, Nair MKC, George B, Sarma PS. Motor and mental development of infants exposed to antiepileptic drug in utero. Epil Behav 2008; 13:229-236.
67. Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001;70:15-21.
68. Vinten J, Bromley RL, Taylor J, Adab N, Kini U, Baker GA, on behalf of the Liverpool and Manchester Neurodevelopment Group. The behavioral consequences of exposure to antiepileptic drug in utero. Epil Behav 2009;14:197-201.
69. Mayes LC, Ward A. Principles of neurobehavioural teratology. In: Cicchetti D,Walker EF, eds. Neurodevelopmental Mechanisms in Psychopathology. Cambridge: Cambridge University Press. 2003:3-34.
70. Walker A, Rosemberg M, Balaban-Gil K. Neurodevelopmental and neurobehavioral sequelae of selected substances of abuse and psychiatric medications in utero. Child Adolesc Psychiatr Clin N Am 1999;8:845-867.
71. Gentile S. Special care-needs for schizoaffective women in childbearing age [Abstract]. Turk J Psychiatry 2006;17:271.
72. Gentile S. Managing the suicidal risk in pregnant women with severe and persistent psychiatric disorder. Focus on antisuicidal drugs and somatic interventions. Curr Psychiatr Rev 2008;4: 169-184.
73. Lösche G, Steinhausen HC, Helge H. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr 1994;83:961-966.
74. Lobstein R, Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: The motherisk experience. J Psychiatry Neurosci 1997:22:192-196.
75. AACAP. Practice parameters for the psychiatric assessment of infant and toddlers (0-36 months). J Am Acad Child Adolesc Psychiatry 1997;36:S21-S36.
76. Meisels SJ, Provence S. Screening and assessment: Guidelines for identifying young disabled and developmentally vulnerable children and their families. Washington, DC: Zero to Three/ National Center for Clinical Infants Program. 1989.
77. Laing JG, Law J, Levin A, Logan S. Evaluation of a structured test and a parent led method for screening for speech and language problem: Prospective population based study [Abstract]. BMJ 2002;325:1152.
78. Wassemberg R, Max JE, Koele SL, Firme K. Classifying psychiatric disorders after traumatic brain injury and orthopaedic injury in children: Adequacy of K-SADS versus CBCL. Brain Inj 2004;18:377-390.
79. Dienes KA, Chang KD, Blasey CM, Adleman NE, Steiner H. Characterization of children of bipolar parents report CBCL. J Psychiatr Res 2002;36:337-345.
80. Gibbs MV, Reeves D, Cunningham CC. The application of temperament questionnaires to a British sample: Issues of reliability and validity. J Child Psychol Psychiatry 1987;28: 61-77.
81. Crowe TK, Deitz JC, Bennett FC. The relationship between the Bayley scales of infant development and preschool gross motor and cognitive performance. Am J Occup Ther 1987;41:374-378.
82. Leonard CH, Piecuch RE, Cooper BA. Use of Bayley infant neurodevelopmental screener with low birth weight infants. J Pediatr Psychol 2001;26:33-40.
83. Huber CJ, Stangler SR, Routh DK. The BOEL test as a screening device for otitis media in infants. Nurs Res 1978;27:178-180.
84. Hadders-Algra M, Heineman KR, Bos AF, Middelburg KJ. The assessment of minor neurological dysfunction in infancy using the Touwen Infant Neurological Examination: Strengths and limitations. Dev Med Child Neurol. 2009. Jun 22. [Epub ahead of print].
85. Ross G. Some thoughts on the value of infant tests for assessing and predicting mental ability. J Dev Behav Pediatr 1989;10: 44-47.
86. Cabrera PM, Grimes-Gaa L, Thyer BA. Social work assessment of adaptive functioning using the vineland adaptive behavior scales: Issues of reliability and validity. J Hum Behav Soc Env 1999;2:33-50.
87. Naar-King S, Ellis DA, Frey MA. Denver II. Assessing Children's Well-Being: A Handbook of Measures. New York: Psychology Press. 2008:133-137.
88. Beke A, Gosy M. Speech perception and speech comprehension investigations of pre-term newborns and high-risk neonates of pre-school age. Child Care Health Dev 1997; 23:457-474.
89. Kahana SY, Youngstrom EA, Glutting JJ. Factor and subtest discrepancies on the differential ability scales: Examining prevalence and validity in predicting academic achievement. Assessment 2002;9:82-93.
90. Velves T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006;62: 863-870.
91. Anderson GM, Czarkowski K, Ravski N, Epperson CN. Platelet serotonin in newborns and infants: Ontogeny, heritability, and effect of in utero exposure to selective serotonin reuptake inhibitors. Pediatr Res 2004;56:418-422.
92. Gentile S. SSRIs in pregnancy and lactation with emphasis on neurodevelopmental outcome. CNS Drugs 2005;19:623-633.
93. Mawer G, Clayton-Smith J, Coyle S, Kini U. Outcome of pregnancy in women attending an outpatient epilepsy clinic: Adverse features associated with higher doses of valproate. Seizure 2002;11:512-518.
94. Battino D. Cognitive outcome after exposure to antiepileptic drugs in utero. Lancet Neurol 2009;8:600-601.
95. Appelbaum PS, Grisso T. The MacArthur Treatment Competence Study: I. Mental illness and competence to consent to treatment. Law Hum Behav 2005;19:105-126.
96. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: A systematic review. J Affect Disord 2010, Mar 18. [Epub ahead of print].
97. Almgren M, Källén B, Lavebratt C. Population-based study of antiepileptic drug exposure in utero-Influence on head circumference in newborns. Seizure 2009;18:672-675.
98. Bromley RL, Mawer G, Clayton-Smith J, Baker GA. Liverpool and Manchester Neurodevelopment Group. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008;71:1923-1924.
99. Fonseca LC, Tedrus GM, Chiodi MG, Cerqueria JN, Tonelotto JM. Quantitative EEG in children with learning disabilities: Analysis of band power. Acta Neuropsiquiatr 2006;64:376-381.
100. Thatcher RW, North D, Biver C. Intelligence and EEG current density using low-resolution electromagnetic tomography (LORETA). Hum Brain Mapp 2007;28:118-133.
101. Fayed M, Morales H, Modrego PJ, Munoz-Mingarro J. White matter proton MR spectroscopy in children with isolated developmental delay: Does it mean delayed myelination? Acad Radiol 2006;13:229-235.